Cardiac amyloidosis (CA) is an infiltrative restrictive cardiomyopathy caused by the deposition of amyloid fibrils in the myocardium. It manifests in two primary subtypes: transthyretin cardiac amyloidosis (ATTR) and immunoglobulin light chain cardiac amyloidosis (AL). ATTR is further classified into wild-type and hereditary based on transthyretin gene mutation. Advances in diagnostics and therapeutics have transformed CA from a rare and untreatable condition to a more prevalent and manageable disease. Noninvasive diagnostic tools such as electrocardiography, echocardiography, and cardiac magnetic resonance can raise suspicion for CA; bone scintigraphy can non-invasively confirm ATTR, while AL necessitates histological confirmation. The severity of ATTR and AL can be assessed through serum biomarker-based staging. Treatment approaches differ, ranging from silencing or stabilizing transthyretin and degrading amyloid fibrils in ATTR to employing anti-plasma cell therapies and autologous stem cell transplantation in AL.
MerliniGBellottiV. Molecular mechanisms of amyloidosis. N Engl J Med2003; 349: 583–596.
2.
FalkRH. Diagnosis and management of the cardiac amyloidoses. Circulation2005; 112: 2047–2060.
3.
MasriABukhariSEiseleYS, et al. Molecular imaging of cardiac amyloidosis. J Nucl Med2020; 61: 965–970.
4.
GriffinJMRosenblumHMaurerMS. Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res2021; 128: 1554–1575.
5.
LuRRichardsTA. AL amyloidosis: unfolding a complex disease. J Adv Pract Oncol2019; 10: 813–825.
6.
PoliLLabellaBCotti PiccinelliS, et al. Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy. Front Neurol2023; 14: 1242815.
7.
KoikeHOkumuraTMuroharaT, et al. Multidisciplinary approaches for transthyretin amyloidosis. Cardiol Ther2021; 10: 289–311.
8.
Gonzalez-LopezEGallego-DelgadoMGuzzo-MerelloG, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J2015; 36: 2585–2594.
9.
CastanoANarotskyDLHamidN, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J2017; 38: 2879–2887.
10.
MauriziNRellaVFumagalliC, et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol2020; 300: 191–195.
11.
TanskanenMPeuralinnaTPolvikoskiT, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med2008; 40: 232–239.
12.
RavichandranSLachmannHJWechalekarAD. Epidemiologic and survival trends in amyloidosis, 1987–2019. N Engl J Med2020; 382: 1567–1568.
13.
ShiJGuanJJiangBBrennerDA, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci USA2010; 107: 4188–4193.
14.
KyleRALinosABeardCM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood1992; 79: 1817–1822.
15.
GroganMScottCGKyleRA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol2016; 68: 1014–1020.
16.
PilebroBSuhrOBNaslundU, et al. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Ups J Med Sci2016; 121: 17–24.
17.
BuxbaumJJacobsonDRTagoeC, et al. Transthyretin V122I in African Americans with congestive heart failure. J Am Coll Cardiol2006; 47: 1724–1725.
18.
ReillyMMStauntonHHardingAE. Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study. J Neurol Neurosurg Psychiatry1995; 59: 45–49.
19.
BonaitiBOlssonMHellmanU, et al. TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance?Eur J Hum Genet2010; 18: 948–952.
20.
ArvidssonSPilebroBWestermarkP, et al. Amyloid cardiomyopathy in hereditary transthyretin V30M amyloidosis – impact of sex and amyloid fibril composition. PLoS One2015; 10: e0143456.
21.
Waddington-CruzMWixnerJAmassL, et al. Characteristics of patients with late- vs. early-onset Val30Met transthyretin amyloidosis from the transthyretin amyloidosis outcomes survey (THAOS). Neurol Ther2021; 10: 753–766.
22.
KoikeHMisuKIkedaS, et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol2002; 59: 1771–1776.
23.
MaurerMSHannaMGroganM, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey). J Am Coll Cardiol2016; 68: 161–172.
24.
DunguJNValenciaOPinneyJH, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging2014; 7: 133–142.
25.
BukhariSOliverosEParekhH, et al. Epidemiology, mechanisms, and management of atrial fibrillation in cardiac amyloidosis. Curr Probl Cardiol2023; 48: 101571.
26.
OyeMDhruvaPKandahF, et al. Cardiac amyloid presenting as cardiogenic shock: case series. Eur Heart J Case Rep2021; 5: ytab252.
27.
DorbalaSVangalaDBruyereJJr, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail2014; 2: 358–367.
28.
NitscheCScullyPRPatelKP, et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol2021; 77: 128–139.
29.
MilandriAFarioliAGagliardiC, et al. Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. Eur J Heart Fail2020; 22: 507–515.
30.
SperryBWReyesBAIkramA, et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol2018; 72: 2040–2050.
31.
WestinOFosbolELMaurerMS, et al. Screening for cardiac amyloidosis 5 to 15 years after surgery for bilateral carpal tunnel syndrome. J Am Coll Cardiol2022; 80: 967–977.
32.
MaurerMSSmileyDSimsoloE, et al. Analysis of lumbar spine stenosis specimens for identification of amyloid. J Am Geriatr Soc2022; 70: 3538–3548.
33.
GellerHISinghAAlexanderKM, et al. Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis. JAMA2017; 318: 962–963.
34.
RubinJAlvarezJTeruyaS, et al. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier?Amyloid2017; 24: 226–230.
35.
DemberLM. Amyloidosis-associated kidney disease. J Am Soc Nephrol2006; 17: 3458–3471.
36.
SharmaABansalSJainR. Unique morphology of intratubular light chain casts in multiple myeloma: the amyloid cast nephropathy. Indian J Pathol Microbiol2014; 57: 629–631.
37.
CiprianiADe MichieliLPorcariA, et al. Low QRS voltages in cardiac amyloidosis: clinical correlates and prognostic value. JACC CardioOncol2022; 4: 458–470.
38.
CyrilleNBGoldsmithJAlvarezJ, et al. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol2014; 114: 1089–1093.
39.
DunguJSattianayagamPTWhelanCJ, et al. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in afro-caribbean patients. Am Heart J2012; 164: 72–79.
40.
MurtaghBHammillSCGertzMA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol2005; 95: 535–537.
41.
DasMKKhanBJacobS, et al. Significance of a fragmented QRS complex versus a Q wave in patients with coronary artery disease. Circulation2006; 113: 2495–2501.
42.
Gonzalez-LopezEGagliardiCDominguezF, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J2017; 38: 1895–1904.
43.
FalkRHAlexanderKMLiaoR, et al. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol2016; 68: 1323–1341.
44.
NagyDReveszKPeskoG, et al. Cardiac amyloidosis with normal wall thickness: prevalence, clinical characteristics and outcome in a retrospective analysis. Biomedicines2022; 10.
45.
VermeerAMCJanssenABoorsmaPC, et al. Transthyretin amyloidosis: a phenocopy of hypertrophic cardiomyopathy. Amyloid2017; 24: 87–91.
46.
Lopez-SainzAde Haro-Del MoralFJDominguezF, et al. Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders. Amyloid2019; 26: 156–163.
47.
PagoureliasEDMireaODuchenneJ, et al. Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging2017; 10: e005588.
48.
PhelanDCollierPThavendiranathanP, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart2012; 98: 1442–1448.
49.
MaceiraAMJoshiJPrasadSK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation2005; 111: 186–193.
50.
FontanaMPicaSReantP, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation2015; 132: 1570–1579.
51.
YangLKreftingIGorovetsA, et al. Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the food and drug administration. Radiology2012; 265: 248–253.
52.
KaramitsosTDPiechnikSKBanypersadSM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging2013; 6: 488–497.
53.
BanypersadSMFontanaMMaestriniV, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J2015; 36: 244–251.
54.
Martinez-NaharroAKotechaTNorringtonK, et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging2019; 12: 810–819.
55.
BanypersadSMSadoDMFlettAS, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging2013; 6: 34–39.
56.
Martinez-NaharroAAbdel-GadirATreibelTA, et al. CMR-verified regression of cardiac AL amyloid after chemotherapy. JACC Cardiovasc Imaging2018; 11: 152–154.
57.
KotechaTMartinez-NaharroATreibelTA, et al. Myocardial edema and prognosis in amyloidosis. J Am Coll Cardiol2018; 71: 2919–2931.
58.
RapezziCGagliardiCMilandriA. Analogies and disparities among scintigraphic bone tracers in the diagnosis of cardiac and non-cardiac ATTR amyloidosis. J Nucl Cardiol2019; 26: 1638–1641.
59.
StatsMAStoneJR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol2016; 25: 413–417.
60.
PeruginiEGuidalottiPLSalviF, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol2005; 46: 1076–1084.
61.
GillmoreJDMaurerMSFalkRH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation2016; 133: 2404–2412.
62.
BokhariSCastanoAPozniakoffT, et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging2013; 6: 195–201.
63.
MasriABukhariSAhmadS, et al. Efficient 1-hour technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis. Circ Cardiovasc Imaging2020; 13: e010249.
64.
FalkRHLeeVWRubinowA, et al. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol1983; 51: 826–830.
65.
MusumeciMBCappelliFRussoD, et al. Low sensitivity of bone scintigraphy in detecting phe64leu mutation-related transthyretin cardiac amyloidosis. JACC Cardiovasc Imaging2020; 13: 1314–1321.
66.
ArdehaliHQasimACappolaT, et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J2004; 147: 919–923.
67.
HolzmannMNickoAKuhlU, et al. Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. Circulation2008; 118: 1722–1728.
68.
GuyCDJonesCK. Abdominal fat pad aspiration biopsy for tissue confirmation of systemic amyloidosis: specificity, positive predictive value, and diagnostic pitfalls. Diagn Cytopathol2001; 24: 181–185.
69.
TakashioSYamamuroMIzumiyaY, et al. Diagnostic utility of cardiac troponin t level in patients with cardiac amyloidosis. ESC Heart Fail2018; 5: 27–35.
70.
GillmoreJDDamyTFontanaM, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J2018; 39: 2799–2806.
71.
KumarSDispenzieriALacyMQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol2012; 30: 989–995.
72.
GilstrapLGDominiciFWangY, et al. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the united states. Circ Heart Fail2019; 12: e005407.
73.
SperryBWSaeedIMRazaS, et al. Increasing rate of hospital admissions in patients with amyloidosis (from the national inpatient sample). Am J Cardiol2019; 124: 1765–1769.
74.
ChanNHannaMMaurerMS. The wiggers diagram: hemodynamic changes in cardiac amyloidosis. J Card Fail2023; 29: 217–219.
75.
GertzMAFalkRHSkinnerM, et al. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol1985; 55: 1645.
76.
GertzMASkinnerMConnorsLH, et al. Selective binding of nifedipine to amyloid fibrils. Am J Cardiol1985; 55: 1646.
77.
RubinowASkinnerMCohenAS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation1981; 63: 1285–1288.
78.
MuchtarEGertzMAKumarSK, et al. Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?Amyloid2018; 25: 86–92.
79.
BukhariSKhanSZBashirZ. Atrial fibrillation, thromboembolic risk, and anticoagulation in cardiac amyloidosis: a review. J Card Fail2023; 29: 76–86.
80.
BukhariSBarakatAFEiseleYS, et al. Prevalence of atrial fibrillation and thromboembolic risk in wild-type transthyretin amyloid cardiomyopathy. Circulation2021; 143: 1335–1337.
81.
El-AmEADispenzieriAMelduniRM, et al. Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. J Am Coll Cardiol2019; 73: 589–597.
82.
HeidenreichPABozkurtBAguilarD, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation2022; 145: e876–e894.
83.
ChungFPLinYJKuoL, et al. Catheter ablation of ventricular tachycardia/fibrillation in a patient with right ventricular amyloidosis with initial manifestations mimicking arrhythmogenic right ventricular dysplasia/cardiomyopathy. Korean Circ J2017; 47: 282–285.
84.
BukhariSKhanSZGhowebaM, et al. Arrhythmias and device therapies in cardiac amyloidosis. J Clin Med2024; 13: 1300.
85.
HigginsAYAnnapureddyARWangY, et al. Survival following implantable cardioverter-defibrillator implantation in patients with amyloid cardiomyopathy. J Am Heart Assoc2020; 9: e016038.
86.
Al-KhatibSMStevensonWGAckermanMJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the heart rhythm society. Heart Rhythm2018; 15: e190–e252.
87.
DonnellanEWazniOMSalibaWI, et al. Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis. Am J Cardiol2020; 128: 140–146.
88.
BukhariSKasiAKhanB. Bradyarrhythmias in cardiac amyloidosis and role of pacemaker. Curr Probl Cardiol2023; 48: 101912.
89.
DonnellanEWazniOMSalibaWI, et al. Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left ventricular function, mitral regurgitation, and mortality. J Cardiovasc Electrophysiol2019; 30: 2427–2432.
90.
ElbashirSMHarborthJLendeckelW, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature2001; 411: 494–498.
91.
AdamsDGonzalez-DuarteAO’RiordanWD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med2018; 379: 11–21.
92.
CrookeSTWangSVickersTA, et al. Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol2017; 35: 230–237.
93.
BensonMDWaddington-CruzMBerkJL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med2018; 379: 22–31.
94.
MaurerMSSchwartzJHGundapaneniB, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med2018; 379: 1007–1016.
95.
BerkJLSuhrOBObiciL, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA2013; 310: 2658–2667.
96.
SekijimaYTojoKMoritaH, et al. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid2015; 22: 79–83.
97.
PenchalaSCConnellySWangY, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V22I transthyretin. Proc Natl Acad Sci U S A2013; 110: 9992–9997.
98.
JudgeDPHeitnerSBFalkRH, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol2019; 74: 285–295.
99.
KarlstedtEJimenez-ZepedaVHowlettJG, et al. Clinical experience with the use of doxycycline and ursodeoxycholic acid for the treatment of transthyretin cardiac amyloidosis. J Card Fail2019; 25: 147–153.
100.
WixnerJPilebroBLundgrenHE, et al. Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis. Amyloid2017; 24: 78–79.
101.
Hasib SidiqiMGertzMA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. Blood Cancer J2021; 11: 90.
102.
DispenzieriABuadiFKumarSK, et al. Treatment of immunoglobulin light chain amyloidosis: Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement. Mayo Clin Proc2015; 90: 1054–1081.
